The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01923428 | Completed Phase 2 Results

• 1 other identifier: D5612C00001
• Study Type: interventional
• Target: 356
• Locations: 1 country
• Sites: 4

Brief Summary

This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III criteria and who have active disease as determined during a two-week screening period. Subjects who qualify and are randomized into the study will receive 5, 20, or 50 mg of AZD1722 BID or placebo BID for 12 consecutive weeks. At the end of this treatment period, subjects will be followed for an additional 4 weeks.

Conditions

Constipation Predominant Irritable Bowel Syndrome

Outcome Measures

Primary Outcomes (1)

• Percent Complete Spontaneous Bowel Movement Responders vs Placebo

  Weekly complete spontaneous bowel movement resaponders defined as an increase of one or more bowel movement per week from baseline for 6 of the 12 weeks

  12 weeks

Study Arms (4)

5 mg BID

EXPERIMENTAL

AZD1722

Drug: AZD1722

20 mg BID

EXPERIMENTAL

AZD1722

Drug: AZD1722

50 mg BID

EXPERIMENTAL

AZD1722

Drug: AZD1722

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

AZD1722 DRUG

Also known as: RDX5791, Tenapanor

20 mg BID; 5 mg BID; 50 mg BID

Placebo DRUG

Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Females and males must agree to use appropriate methods of contraception or be sterile (with appropriate documentation)
• Subject is ambulatory
• Subject meets definition of IBS-C using Rome III Criteria for the Diagnosis of IBS with a history of \<5 SBMs per week
• Subject meets Screening eligibility criteria (see below)
• A colonoscopy based on AGA guidelines; every 10 years at ≥ 50 years old, or the occurrence of any warning signs (i.e., unexplained weight loss, non-hemorrhoid blood in stools)
• Ability to communicate well with the Investigator and to comply with the requirements of the entire study, including an understanding of how to use the touch-tone telephone electronic diary.
• Written informed consent and a willingness to participate in the study as it is described.
• Daily access to a touch tone telephone.

You may not qualify if:

• Functional diarrhea as defined by Rome III criteria
• IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome III criteria
• Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening. Including but not limited to cancer, inflammatory bowel disease, diverticulitis, duodenal ulcer, erosive esophagitis, gastric ulcer, pancreatitis (within 12 months of screening), cholelithiasis, amyloidosis, ileus, non-controlled GERD, gastrointestinal obstruction or carcinoid syndrome.
• Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics within 4 weeks of enrollment, probiotics (including probiotic yogurt); or salt or electrolyte supplements containing sodium, potassium, chloride, or bicarbonate formulations during the seven days prior to treatment; unless specified as rescue medication, and used accordingly.
• Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurologic, psychiatric or any disease that may interfere with the subject successfully completing the trial.
• The subject has a history or current evidence of laxative abuse (in the clinical judgment of the physician).
• Hepatic dysfunction (ALT \[SGPT\] or AST \[SGOT\] \>2.5 times the upper limit of normal) or renal impairment (serum creatinine \> 2mg/dL).
• Any evidence of or treatment of malignancy (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year.
• Any surgery on the stomach, small intestine or colon, excluding appendectomy.
• Pregnant or lactating women.
• A major psychiatric disorder (DSM-III-R or DSM-IV) including major depression or other psychoses that has required hospitalization in the last 3 years. History of attempted suicide or uncontrolled bipolar disorder. Alcohol or substance abuse in the last year.
• Participation in other clinical trials within 1 month prior to Day -14 (beginning of screening period).
• If, in the opinion of the Investigator the subject is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable.

Sponsors & Collaborators

• Ardelyx: lead

Study Sites (4)

Unknown Facility

Boulder, Colorado, United States

Location

Unknown Facility

Greensboro, North Carolina, United States

Location

Unknown Facility

Winston-Salem, North Carolina, United States

Location

Unknown Facility

Chattanooga, Tennessee, United States

Location

Related Publications (1)

• Lacy BE, Shin AS, Cangemi DJ, Yang Y, Zhao S, Rosenbaum DP. Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis. Therap Adv Gastroenterol. 2026 Jan 24;19:17562848251414831. doi: 10.1177/17562848251414831. eCollection 2026.

  PMID: 41601848 DERIVED

MeSH Terms

Interventions

tenapanor

Results Point of Contact

• Title: Chief Development Officer
• Organization: Ardelyx

drosenbaum@ardelyx.com

510 745 1752

Study Officials

• David P Rosenbaum, Ph.D.

  Ardelyx, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 13, 2013
• First Posted: August 15, 2013
• Study Start: August 1, 2013
• Primary Completion: October 1, 2014
• Study Completion: October 1, 2014
• Last Updated: April 8, 2020
• Results First Posted: January 10, 2020

Record last verified: 2020-03

Locations

US (4)